Tourette Syndrome Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented by Product (Antipsychotics and Non-Antipsychotics), and Geography

Market Snapshot

Study Period:

2016-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Major factors driving the growth of the market is increasing cases of Tourette syndrome all across the world. As per the data of CDC study, 1 of every 360 (0.3%) children 6-17 years of age in the US have received a diagnosis of TS, which is about 138,000 children. Also among children diagnosed with TS, 37% have been reported as having moderate or severe forms of the condition. In addition, it has been found that boys are three to five times more likely to have TS than girls. Non-Hispanic white children are also twice as likely to have a TS diagnosis as Hispanic and non-Hispanic black children.

Apart from the rising cases of tourette syndrome, increasing focus on tourette syndrome research is anticipated to contribute significant growth to the studied market.

 

Scope of the Report

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The report covers the market trends of treatment of tourette syndrome using antipsychotics and non-antipsychotics.

Product
Antipsychotics
Haloperidol
Fluphenazine
Benzamide
Clozapine
Olanzapine
Others
Non Antipsychotics
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Antipsychotic dominates the Global Tourette Syndrome Treatment Market

The robust therapeutic effect of antipsychotics is one of the significant factors driving the growth of the Tourette's syndrome treatment market.  The most commonly prescribed drugs are mainly dopamine antagonists, like neuroleptics (e.g. haloperidol), benzamides (e.g. sulpiride) or atypical antipsychotics (e.g. risperidone). Also, there are other drugs that proven to be effective in treating tourette include drugs that are the modulators of noradrenaline (e.g. clonidine), GABA (e.g. benzodiazepines) and acetylcholine (e.g. nicotine).

However, future collaborations among clinical sites with tourette syndrome expertise employing high-quality study design might clarify the role of atypical antipsychotics for the treatment of TS in a better way. The dopamine antagonists may lead to the most reliable treatment response but also can cause severe side effects.

To understand key trends, Download Sample Report

North America Dominates the Global Tourette Syndrome Treatment Market

According to the CDC data, about 140,000 children aged 6 to 17 years in the United States have ever been diagnosed with TS. Advanced healthcare facilities, rising knowledge, better screening has been contributing significant growth to the US market. Also, CDC works with the Tourette Association of America to increase access to CBIT (Comprehensive Behavioral Intervention for Tics), provide education and outreach efforts, improve acceptance and lessen stigma through the Tourette Association Youth Ambassador Program and also offer resources to help individuals and families living with Tourette including school resources.

To understand geography trends, Download Sample Report.

Competitive Landscape

Tourette Syndrome Treatment market is very competitive with most of the players competing to increase market shares. Rising  competition, rapid technological advancements, focus on research is key factors that have strong impact on the market. Key market players in the market are AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd, Neurocrine Biosciences, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Cases of Tourette Syndrome

      2. 4.2.2 Rising Focus on Tourette Syndrome Research

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness in Developing Region

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Product

      1. 5.1.1 Antipsychotics

        1. 5.1.1.1 Haloperidol

        2. 5.1.1.2 Fluphenazine

        3. 5.1.1.3 Benzamide

        4. 5.1.1.4 Clozapine

        5. 5.1.1.5 Olanzapine

        6. 5.1.1.6 Others

      2. 5.1.2 Non Antipsychotics

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 US

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 UK

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc

      2. 6.1.2 Boehringer Ingelheim International GmbH

      3. 6.1.3 Eli Lilly and Co.

      4. 6.1.4 Mylan NV

      5. 6.1.5 Otsuka Holdings Co. Ltd.

      6. 6.1.6 Sanofi S.A.

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sun Pharmaceutical Industries Ltd

      9. 6.1.9 Neurocrine Biosciences, Inc.,

      10. 6.1.10 Novartis AG

      11. 6.1.11 Teva Pharmaceutical Industries Ltd.

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports